Skip to content

Ayurvedic management of migraine

Evaluation of Neurogrex Capsule on Shirahshoola (Headache/Migraine)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012832
Enrollment
60
Registered
2018-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- migraine headache

Interventions

Intervention1: Neurogrex capsule: Dose one tablet morning one tablet afternoon two tablet nigt After food Route of administration oral Duration one month Follow up one month Contents Shuddh Hingul Shu

Sponsors

IPGT and RA jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients in the age group 18 to 60 years, presenting with signs and symptoms of Shirahshoola described as per Ayurveda and modern science will be included in the study. 2. The diagnosis of the disease shall be done on the basis of clinical manifestations like recurrent attacks of headache, mostly unilateral in site, variable in intensity, frequency and duration with or without nausea, vomiting, aura and GI tract symptoms.

Exclusion criteria

Exclusion criteria: 1. Patients suffering from any chronic debilitating disease, with other neurological pathology and cases which required surgical intervention will be excluded from study. 2. Patients suffering from Sinusitis, Hypertension, Secondary headache caused by meningitis, tumor, encephalitis, cervical spondylitis and refractive errors will be excluded from study. 3. Patients using any other systemic drugs which may alter the results of study.

Design outcomes

Primary

MeasureTime frame
Severity of Headache Frequency of Headache Assessed in term of (frequency in days) Duration of Headache (Assessed in term of hours/day) Nausea Vomiting Vertigo AuraTimepoint: The assessment will be done before treatment one month after treatment and one month after completion of the treatment at fortnight interval

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactD B Vaghela

IPGT & RA, Jamnagar

drvaghela@rediff.mail.com9825407899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026